FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes

The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.
Source: Food and Drug Administration - Category: American Health Source Type: news